neurocrin report dilut ep revenu compar
street estim respect recal pre-announc
ingrezza sale though would behoov provid concret
net sale guidanc ingrezza particularli context product sale
annual would interpret absenc guidanc rang
suggest challeng outlook quit contrari continu believ
size underli tardiv dyskinesia td popul rel favor payer
landscap two approv agent point ampl room continu aggress
ingrezza sale growth commentari surround season deduct
reset notwithstand reiter overweight rate lower pt
owe primarili higher oper expens estim
latest detail ingrezza sale volum recal part last month pre-
announc report ingrezza prescript rx around
compar rx respect
refer note detail net realiz price per rx around
similar saw manag note net price would
somewhat weaker wider gross-to-net spread owe annual
deduct reset greater subsid patient out-of-pocket cost common
phenomenon across industri impact medicar part donut hole
result sale headwind versu would keep
mind ingrezza contract product would expect see
averag spread teen higher moder
year progress case
phase ii data congenit adren hyperplasia loom
reiter data proof-of-concept studi evalu
oral corticotropin-releas hormon antagonist adult
expect later multi-dos dose-escal studi evalu once-daili
administr day manag also reiter plan studi
pediatr patient later year
keep close eye next-gener vesicular monoamin
transport inhibitor note recent complet dose singl
ascend dose portion phase studi evalu next-gener
inhibitor initi dose multipl ascend dose portion studi
continu believ potenti signific valu anoth next-gener
inhibitor bear mind wide rang neurolog psychiatr diseas
dopaminerg etiolog least part
clinic commerci setback relat ingrezza product
neurocrin focus therapi neurolog endocrin diseas
price close februari
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu pjc consensu estim
consensu estim
compani report factset research pjc estim
page
million except per shareactualpjc product royalti licens fee incom expens tax benefit incom outstand exhibit
consensu estim
compani report factset research pjc estim
lower pt
new pt base price-to-earnings unchang ep estim
discount unchang three year unchang
revis estim primarili reflect increas spend associ recent announc
collabor agreement voyag cover well greater sg
spend associ signific sale market support ingrezza td along
pre-launch spend opicapon new pt translat price-to-earnings
note lever believ appropri context view
transform long-term growth cash flow ingrezza continu ramp believ peak
 sale ingrezza north realist royalti orilissa grow
time bear mind outsid opicapon model reflect contribut
pipelin shots-on-go
page
million except per tardiv licens fee incom expens tax incom outstand quarterli annual incom statement
million except ep
mileston licens fee
sale
incom loss tax
expens total product sale
sale
gener administr
reflect mileston payment follow submiss snda file elagolix uterin fibroid
proprietari piper jaffray februari
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
